Jaguar Health, Inc. (JAGX): Entry into a Material Definitive Agreement
Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d144017dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Certain identified information marked as [****] has been excluded from this exhibit because it both (i) is not material and (ii) is the type that the Company treats as private or confidential. MANUFACTURING AND SUPPLY AGREE
How this was made
The 30-second read
Why it matters
For JAGX, the practical trading question is whether the agreement improves supply reliability and cost for Crofelemer Final, the active ingredient used in Mytesi, and whether it introduces new execution or quality risks.
Market read
This is a fresh SEC contract disclosure that may affect operational supply risk for Mytesi, but the excerpt provides limited financial detail due to redactions.
What to watch
Key redacted sections likely contain pricing, minimum purchase quantities, quality/regulatory obligations, and termination or chronicity/supply-failure remedies that determine real risk and value.
Background
The 8-K reports Item 1.01, entry into a material definitive manufacturing and supply agreement between Alivus Life Sciences Limited and Jaguar’s wholly owned subsidiary Napo Pharmaceuticals.
Ticker impact
Jaguar Health entered a material definitive manufacturing and supply agreement for Crofelemer Final used in its FDA-approved Mytesi product.
Near-term impact is likely limited unless the agreement includes specific commercial terms or capacity guarantees not shown in the excerpt; longer-term sentiment depends on supply reliability and cost structure.
The filing confirms a material definitive agreement but the provided text excerpt omits key commercial details (many terms are redacted), limiting the ability to quantify financial impact.
Market effects
Highlights ongoing reliance on contract manufacturing for specialty pharma products, which can influence perceived operational resilience in the segment.
Involves an India-based manufacturer (Alivus), which may matter for supply-chain and regulatory quality perceptions.
Cross-border manufacturing arrangements can affect continuity of supply for FDA-approved therapies, relevant to broader specialty pharma supply risk.
Counterpoint
A “material” agreement may still be largely administrative or replace an existing arrangement, so the market may not re-rate the stock without clearer financial or capacity terms.
Key entities
- public_companyJaguar Health, Inc.
Subject of the 8-K, disclosing entry into a material definitive manufacturing and supply agreement via its subsidiary Napo.
- subsidiaryNapo Pharmaceuticals, Inc.
Wholly owned subsidiary of Jaguar that contracts for manufacturing and supply of Crofelemer Final.
- counterpartyAlivus Life Sciences Limited
India-based manufacturer and supplier of Crofelemer Final under the agreement.
